Stock Markets7 minutes ago (Jun 30, 2021 11:30AM ET)© Reuters. Up 50% in the Past Year, is Insulet Stock a Buy?
Insulin management provider Insulet (NASDAQ:PODD) has seen its stock rise over 50% in the past year as the demand for insulin solutions continues to grow. But does this stock’s fundamentals merit this kind of valuation? Read more to learn if this stock is still a buy.Insulet (PODD), a developer, maker, and marketer of insulin management systems, had a stellar year. PODD is up 9% in the past six months and up more than 51% in the past year.
Will PODD’s good fortune continue? Or will profit taking send PODD lower? These are the pressing questions investors are pondering following PODD’s epic upward run.
Below, I delve into the nuances of PODD to provide investors with what might be in store for the stock in the months ahead. Here is a quick look at PODD as it currently stands following a banner year.